{"nctId":"NCT00594165","briefTitle":"An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.","startDateStruct":{"date":"2002-06"},"conditions":["Early-Stage Parkinson's Disease"],"count":217,"armGroups":[{"label":"Rotigotine","type":"EXPERIMENTAL","interventionNames":["Drug: Rotigotine"]}],"interventions":[{"name":"Rotigotine","otherNames":["Neupro"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who have completed six months of maintenance treatment in the SP512 double-blind trial\n\nExclusion Criteria:\n\n* Subjects who had an ongoing serious adverse event from SP512 double-blind trial that was assessed as related to study medication","healthyVolunteers":false,"sex":"ALL","minimumAge":"31 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With at Least One Adverse Event During This Open-label Extension Study","description":"Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"214","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Withdrew From the Trial Due to an Adverse Event.","description":"Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Epworth Sleepiness Scale Score During the Open-label Extension.","description":"The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"4.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.9","spread":"4.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"5.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4","spread":"5.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"5.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"5.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"5.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":102,"n":216},"commonTop":["Somnolence","Oedema peripheral","Fall","Nausea","Dizziness"]}}}